- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07951424
Clinical Utility Pilot Of Thyroid GuidePx
The purpose of this research study is learn about the effects of Thyroid GuidePx® on papillary thyroid cancer treatment recommendations when the test result is disclosed after surgery.
연구 개요
상세 설명
Primary Objectives:
To determine the decision impact of Thyroid GuidePx® when results are disclosed postoperatively, defined across three prespecified decision domains:
- Extent of initial surgery (counterfactual): (i) among patients who actually had a total thyroidectomy, through the post-test clinician survey, whether Thyroid GuidePx® results would have changed surgical extent and lobectomy would have been appropriate. This includes patients who underwent intraoperative conversion from lobectomy to total thyroidectomy due to gross extrathyroidal extension or unexpected central nodal metastases. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation.
- Completion thyroidectomy: whether Thyroid GuidePx® results change the recommendation to perform completion thyroidectomy or not to perform completion thyroidectomy.
- Adjuvant RAI: Whether Thyroid GuidePx® results change the recommendation to administer postoperative RAI or not to administer postoperative RAI.
Secondary Objectives:
- To estimate the proportion of decision changes within each prespecified domain and the net direction (escalation vs de-escalation).
- To explore clinician- and patient-reported drivers of decision change.
- To assess postoperative decisional regret following disclosure of Thyroid GuidePx® results using the Decisional Regret Scale (DRS), and to explore associations with surgical extent and molecular risk category.
- To compare the proportion of patients who had a completion thyroidectomy in patients who underwent Thyroid GuidePx® testing to historical controls.
- To compare recurrence outcomes in patients whose treatment was de-escalated based on Thyroid GuidePx® result to matched historical controls at the same institution.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Anastasios Maniakas, MD
- 전화번호: 713-792-4351
- 이메일: amaniakas@mdanderson.org
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- UT MD Anderson
-
연락하다:
- Anastasios Maniakas, MD
- 전화번호: 713-792-4351
- 이메일: amaniakas@mdanderson.org
-
수석 연구원:
- Anastasios Maniakas, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
UT MD Anderson
설명
Inclusion Criteria:
disease who can potentially be treated with lobectomy will be recruited to the study. Lobectomy-candidate status is determined by the treating physician using standard institutional criteria (e.g., tumor 1-4 cm, cN0/Nx, no gross ETE). Patients may still undergo total thyroidectomy as part of shared decision-making.
Inclusion criteria:
-
Patients aged 18 years or older at the time of enrollment
-
English-speaking
-
Bethesda V or VI cytology following FNA of a thyroid nodule (papillary thyroid cancer)
-
Preoperative candidacy for lobectomy
- Tumor 1 - 4 cm in size
- No known nodal metastasis
- No gross extrathyroidal extension (ETE) on ultrasound
-
Any of the following intraoperative or surgeon-dependent variations are permitted:
- Prophylactic ipsilateral central neck dissection performed at the surgeon's discretion
- Therapeutic central neck dissection for unexpected central node metastases
- Intraoperative conversion to total thyroidectomy (e.g., gross ETE, multiple large central nodes)
-
Able to undergo intraoperative FNA collection for research testing
Exclusion Criteria:
- Prior thyroid operation
- Distant metastatic disease
- Personal history of thyroid cancer
- History of whole-body radiation exposure or radiation to the head and neck region
- Preoperatively known central or lateral lymph node metastasis
- Receipt of total thyroidectomy is not an exclusion if preoperative features otherwise meet lobectomy-candidate criteria
Patients remain eligible if unexpected central nodal disease is identified intraoperatively or if the surgeon elects to perform a prophylactic ipsilateral central neck dissection, as these scenarios are compatible with initial lobectomy candidacy at MD Anderson.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: CASE_ONLY
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
All Patients
Eligible participants will be identified during standard preoperative evaluation for thyroid nodules or confirmed PTC, following cytological diagnosis (Bethesda V or VI). |
Participants will be offered enrollment in this study, in which Thyroid GuidePx® will be performed on an intraoperative FNA (ioFNA) collected during surgery, with results disclosed postoperatively. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Decision Impact. There are three domain-specific endpoints
기간: Through study completion; an average of 1 year
|
Extent of initial surgery (counterfactual). (i) Among patients who actually had total thyroidectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, would have changed surgical extent. Specifically, if lobectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential de-escalation. (ii) Among patients who actually had a lobectomy, the post-test clinician survey will record whether, knowing the Thyroid GuidePx® result, total thyroidectomy would have been appropriate (Yes/No), providing a counterfactual measure of potential treatment escalation. b) Completion thyroidectomy. Proportion with a change in recommendation (Yes→No or No→Yes). c) Adjuvant RAI. Proportion with a change in recommendation (Yes→No or No→Yes) and intended dose if Yes. |
Through study completion; an average of 1 year
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Anastasios Maniakas, MD, UT MD Anderson
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .